<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000773</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 227</org_study_id>
    <secondary_id>11204</secondary_id>
    <nct_id>NCT00000773</nct_id>
  </id_info>
  <brief_title>Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children</brief_title>
  <official_title>Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the safety, tolerance, and pharmacokinetics of a new improved microparticulate&#xD;
      suspension formulation of atovaquone administered at one of two dose levels (per 09/30/94&#xD;
      amendment, a third dose level was added) daily for 12 days in HIV-infected and perinatally&#xD;
      exposed (per 8/9/95 amendment) infants and children who are at risk of developing&#xD;
      Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
      Atovaquone has shown prophylactic potential in adults in the treatment of PCP but is poorly&#xD;
      absorbed in tablet form. To improve the bioavailability of atovaquone, a new formulation has&#xD;
      been prepared as a microparticulate suspension. Since studies in adults have demonstrated&#xD;
      substantial safety of this drug, evaluation in children is being pursued.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atovaquone has shown prophylactic potential in adults in the treatment of PCP but is poorly&#xD;
      absorbed in tablet form. To improve the bioavailability of atovaquone, a new formulation has&#xD;
      been prepared as a microparticulate suspension. Since studies in adults have demonstrated&#xD;
      substantial safety of this drug, evaluation in children is being pursued.&#xD;
&#xD;
      Three cohorts of four patients each (ages 2-12 years, 3 months to less than 2 years, and 1&#xD;
      month to less than 3 months) receive atovaquone daily for 12 days. The oldest age group is&#xD;
      treated first. In the absence of unacceptable toxicity, the dose of atovaquone is escalated&#xD;
      in subsequent 4-patient cohorts representing each of the age stratifications and (per 9/30/94&#xD;
      amendment) in a separate 4-patient cohort aged 3 months to less than 2 years. If two of four&#xD;
      patients in a given cohort experience unacceptable toxicity at the initial dose, two&#xD;
      additional patients in the same age range are entered. Blood samples are drawn for&#xD;
      pharmacokinetic evaluation. Patients are followed to day 24. Per 9/30/94 amendment, patients&#xD;
      aged 3 months to less than 2 years of age who received one of the lower doses may re-enroll&#xD;
      in the higher dose cohort after a 1-month washout.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 1996</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atovaquone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Dideoxycytidine (zalcitabine; ddC).&#xD;
&#xD;
          -  Didanosine (ddI).&#xD;
&#xD;
          -  Nonaminoglycoside, nonmacrolide, and nonsulfonamide antibiotics.&#xD;
&#xD;
          -  Factor VIII.&#xD;
&#xD;
          -  IVIG.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  AIDS, documented HIV infection, perinatal exposure to HIV, or risk of developing PCP.&#xD;
&#xD;
          -  Normal EKG and chest radiograph.&#xD;
&#xD;
          -  No blood or protein on urinalysis.&#xD;
&#xD;
          -  Consent of parent or guardian.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prophylactic TMP/SMX if given no less than 3 days prior to study entry.&#xD;
&#xD;
          -  Prophylactic aerosolized pentamidine (or a single intravenous dose of 4.0 mg/kg&#xD;
             pentamidine) if given no less than 7 days prior to study entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Anticipated organ system or laboratory abnormalities (other than immune system&#xD;
             abnormalities) from the primary disease and its treatment during the study.&#xD;
&#xD;
          -  Acute or chronic infections requiring treatment during the study. NOTE:&#xD;
&#xD;
          -  Thrush and herpes labialis are allowed if these conditions do not require treatment.&#xD;
&#xD;
          -  Diarrhea or vomiting.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Trimethoprim/sulfamethoxazole.&#xD;
&#xD;
          -  Sulfadoxine and pyrimethamine (Fansidar).&#xD;
&#xD;
          -  Primaquine.&#xD;
&#xD;
          -  Aspirin.&#xD;
&#xD;
          -  Amphotericin B.&#xD;
&#xD;
          -  Aminoglycoside antibiotics.&#xD;
&#xD;
          -  Sulfonamides.&#xD;
&#xD;
          -  Dapsone.&#xD;
&#xD;
          -  Benzodiazepines.&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Erythromycin, clarithromycin, and azithromycin.&#xD;
&#xD;
          -  Digitalis.&#xD;
&#xD;
          -  Para-aminosalicylic acid (PAS).&#xD;
&#xD;
          -  Isoniazid.&#xD;
&#xD;
          -  Anticoagulants.&#xD;
&#xD;
          -  Any other investigational therapies.&#xD;
&#xD;
        Patients with the following prior condition are excluded:&#xD;
&#xD;
          -  History of G6PD deficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hughes W</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Dorenbaum A</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Pediatric AIDS CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Children's CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane/LSU Maternal/Child CRS</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DUMC Ped. CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude/UTHSC CRS</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dorenbaum A, Sadler BM, Xu J, Van Dyke RB, Wei LJ, Moye J, McNamara J, Yogev R, Diaz C, Hughes W. Phase I safety and pharmacokinetics (PK) study of micronized atovaquone (m-ATQ) in HIV exposed or infected infants and children. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:117 (abstract no 288)</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Antifungal Agents</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Biological Availability</keyword>
  <keyword>atovaquone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atovaquone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

